Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFD | P00746 | 16/20 | 0.35 |
| ▸ | PSMB9 | P28065 | 1/20 | 0.34 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | XIAP | P98170 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24665821 | 1.00 | CFD (0.35) | CFDPSMB9DRD2XIAPCYP3A4 | |
| SCHEMBL29230659 | 1.00 | CFD (0.35) | CFDPSMB9DRD2XIAPCYP3A4 | |
| SCHEMBL29231341 | 0.92 | CFD (0.38) | CFDPSMB9XIAP | |
| SCHEMBL24665428 | 0.92 | CFD (0.38) | CFDPSMB9XIAP | |
| SCHEMBL24666217 | 0.92 | CFD (0.38) | CFDPSMB9XIAP | |
| SCHEMBL24666276 | 0.92 | CFD (0.38) | CFDPSMB9XIAP | |
| SCHEMBL29820836 | 0.89 | EP300 (0.34) | CFDPSMB9DRD2XIAPCYP3A4 | |
| SCHEMBL29231327 | 0.89 | EP300 (0.34) | CFDPSMB9DRD2XIAPCYP3A4 | |
| SCHEMBL30341273 | 0.89 | EP300 (0.34) | CFDPSMB9DRD2XIAPCYP3A4 | |
| SCHEMBL26816491 | 0.89 | EP300 (0.34) | CFDPSMB9DRD2XIAPCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117956985-A | Inhibitors of glycogen synthase 1 (GYS 1) and methods of use thereof | 梅兹治疗公司 | 2024-04-30 | — | — | CN | disclosed |
| EP-4308095-A1 | INHIBITORS OF GLYCOGEN SYNTHASE 1 (GYS1) AND METHODS OF USE THEREOF | Maze Therapeutics, Inc. (US) | 2024-01-24 | — | — | EP | disclosed |
| WO-2022198196-A1 | INHIBITORS OF GLYCOGEN SYNTHASE 1 (GYS1) AND METHODS OF USE THEREOF | MAZE THERAPEUTICS, INC. (US) | 2022-09-22 | — | — | WO | disclosed |